Alcon has become an assembly line

Discussion in 'Alcon' started by Anonymous, Mar 13, 2014 at 11:08 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Fack it, smoke em if you got em, this ship is sinking.
     

  2. Anonymous

    Anonymous Guest

     
  3. Anonymous

    Anonymous Guest

    Destroying anything takes very little time; especially so for people with very little knowledge of what they are doing. Legacy Alcon manufacturing processes were relatively robust - not because they followed some fancy acronym such as QbD, but because of the knowledge (mostly capable employee generated, trade secrets) that went into it.
    All that knowledge disappeared when Novartis took over. Contrary to what is propagandized, there is NO comparison between a thorough mechanistic and molecular understanding of processes and ingredients and the legerdemain that is QbD (which is why it is so avidly advocated by fools passing as 'scientists').
     
  4. Anonymous

    Anonymous Guest

    Well said.
    This is the downside of vast amounts of computing power. People with no knowledge of processes can claim to predict key variables from computer generated equation coefficients! Sad - really.
     
  5. Anonymous

    Anonymous Guest

    It's review time in manufacturing. I'm just gonna grab some popcorn and wait for this thread to blow up with threats of unionization again...
     
  6. Anonymous

    Anonymous Guest

    Big Pharma like Novartis does not want or need intelligent people. It wants robots to keep the myth of 'cutting edge research' - and hence - exorbitant prices alive. The profit margins in pharma are gargantuan. As has been aptly pointed out earlier in this post, big pharma can buy cutting edge disruptive technology and/or science from small incubator or biotech companies where the 'real' talent resides. Big Pharma has essentially completed its transition to an investment company much like Chase. Companies like Valeant are the new pharma - unapologetically brash, investment friendly and research devoid.

    Big Pharma has essentially become the middleman of the drug business. It will take much more than hastily assembled, poorly thought and haphazardly implemented policies as the likes of Obamacare to dismantle this useless apparatus that is essentially a huge 'reverse Robin Hood scheme'.
     
  7. Anonymous

    Anonymous Guest

    where are our goals alcon? it is the end of april
     
  8. Anonymous

    Anonymous Guest

    How to alienate friends and intimidate people (with apologies to Dale Carnegie). R.I.P Alcon.
     
  9. anonymous

    anonymous Guest

    Selling me-too versions of older drugs necessarily requires action (without contemplation), brash, cocky, presumptuous, in-the-box masquerading as out-of-the-box personalities. Fresh-out-of-college archetypal "American exceptionalism" type of fools fit that bill.
    Au Revoir to sales reps with some shred of decency still left! Leave before you are forcibly turned to the dark side!
     
  10. anonymous

    anonymous Guest

    RIP Alcon. January will begin the piecemeal sell off by fools that are currently doing a 'deep analysis of the Alcon business".
     
  11. anonymous

    anonymous Guest

    Here's a top -10 list of what may have happened on the pharma side had NVS left Alcon and its competent employees alone: As someone has rightly said - the saddest words in the English language are - 'what might have been'.

    1. Non-preservative multi dose containers
    2. topical drops to replace injectable VEGF blocking medications
    3. significant advances in the understanding of the mechanisms behind ARMD
    4. self correcting implantable lenses
    5. improved methods of sustained delivery to the vitreous humor
    6. improved antifungal and antiviral drugs (ADME, toxicity profile, posology and mechanisms)
    7. leveraging of oral antioxidants into a large scale prophylactic business
    8. engineered surfaces for disposable contact lenses
    9. Better manufacturing methods, including eliminating sterile solids addition for suspensions - instead relying on in-situ formation of suspended particle of defined size and morphology
    10. Improved diagnostics (including the long term vision of the Google) diabetic retinopathy paradigm...........
     
  12. anonymous

    anonymous Guest

    Cool story bro, but having spent some time on your manufacturing floor; you're 10 years behind the curve at absolute best. Now the math works if these things were on the cusp when NVS took the helm and intentionally drove them into the ground for some reason. That would imply that they intentionally sabotaged their 50 billion dollar investment, which is doubtful for a mgmt firm such as NVS. You're living in a dream if you think Alcon manufacturing was anywhere near cutting edge during the entire 21st century. Tone down the autofellatio, your relevance was over a long time ago, you missed the boat; and the sins of your past have come home to roost. No doubt it's a sad story with huge local and personal impact, but it's clearly mapped by a series of nearsighted and greedy decisions. Unfortunately your demise will be a slight ripple in the big picture.
     
  13. anonymous

    anonymous Guest

    NVS has made their investment in manufacturing: a quarter billion for dailies. Everybody else is pretty much dead meat.
     
  14. anonymous

    anonymous Guest

     
  15. anonymous

    anonymous Guest

    If you are implying that the quality of management is directly proportional to the revenue; you are mistaken. The behemoth is hard to take down due to seer size (revenue), not due to fighting skill. Once organizations get to a certain revenue intake, success (for a certain time period) becomes despite - rather than because of - any management relevance. So, while Novartis may not intentionally have set out to kill the goose that laid the golden egg - it most certainly did drive off talent that was critical to the LONG TERM success of Alcon.
    It essentially comes down to a choice between a long term, well thought out, carefully executed growth plan versus near-term, share price inflating, knee-jerk, forever changing tactics. The latter inevitably lends itself to the 'hire-and-fire' 'strategy' for which no management experience is necessary.
     
  16. anonymous

    anonymous Guest

    If it ain't broke - don't fix it
    Knowledge workers are not assembly workers
    Fear and intimidation cannot motivate knowledge workers
    - in fact, they have the opposite effect
    Do not allow people seeped in dictatorial cultures to run knowledge companies